Program & Webcasts
- Phase III KATHERINE Clinical Trial Crossed Early Reporting Boundary and Met its Primary Endpoint
- Slides
- These findings will be simultaneously published in the New England Journal of Medicine.
- Kommentar Prof. Dr. med. Sibylle Loibl, Frankfurt (Siehe Webcast u)nten)
- Adjuvant Capecitabine Did Not Significantly Improve Outcomes for Patients With Early-stage Triple-negative Breast Cancer